(SHRI R. K. JAICHANDRA SINGH): (a) The prices notified under the Drugs (Prices Control) Order, 1979 are Rs. 224 per kg. for Analgin and Rs. 1273.55 per Kg. for Pyrazianamide. As Dipyridamol bulk drug is not produced in he Country, no price is required to be fixed under the Drugs (Prices Control) Order, 1979.

(b) The prices of formulations of Analgin and Pyrazinamide are based on the notified prices referred to in reply to Part (a) and the price of formulations based on Dipyridamol are based on the landed cost of import.

(c), (e) and (f) It came to the notice of the Government that M|s. Hoechst have procured Analgin at a price lower than the Government notified price, and that M|s. German Remedies were importing Dipridamol at a price higher than the price at which it is available from other sources. Notices for recovery of the difference between the price of the bulk drugs allowed in the formulations and actual procurement price have been issued and the process of recovery is on in accordance with the then due procedure of Law.

(d) Sales turn-over, pack-wise and formulator-wise is not monitored by the Government.

Letter of intent for Cephalexin

970. DR. JOSEPH LEON D'SOUZA. Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 1248 given in the Rajya Sabha on 13th May, 1985 and state:

(a) what are the main considerations on which Glaxo have been granted letter of intent for Cephalexin;

(b) whether it is a fact that already Indian companies were granted permissions to manufacture this drug in the country more than the requirement of the country;

(c) whether it is also a fact that Glaxo is marketing formulations based on this drug after getting the bulk drug imported from their principals abroad through Price exempted unit under the arrangement of transfer pricing;

(d) whether this fact along with installation of plant and machinery unauhorisedly, production of formulations without any authority as well as over-charging the prices by this company were kept in mind before granting of letter of intent for Cephalexin; and

(e) if so, how fresh permissions are being granted under such past record and what are the details of each irregularity?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a),)b), (d), and (e) M/s. Glaxo Labs. and some Indian companies have been issued letter of intents for the manufacture of Cephlexin as per the provision of 1978 Drug Policy| Licensing Policy. Details regarding production of item of doubtful validity and unauhorise dinsallation of plant and machinery by Glaxo have been furnished in reply to Rajya Sabha Unstarred Question No. 486 dated 30th April, 1984 and Question No. 161 dated 18th November 1985.

(c) Yes, Sir. However there is so evidence to show transfer pricing.

Manufacture of Griseofluvin by IDPL

971. DR. JOSEPH LEON D'SOUZA: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 1304 given in the Rajya Sabha on 13th May, 1985 and state.

(a) whether IDPL purchased the technology for the manufacture of Griseofluvin;

(b) if so, the amount paid along with the source of purchase;